| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2012-03-27 | Bayer (Germany) Tsinghua University (China) | understanding of disease mechanisms, identification of new drug targets and structural biology research and medicinal chemistry programs | R&D |
R&D agreement | ||
| 2012-03-26 | Almirall (Spain) Menarini (Italy) | aclidinium bromide | chronic obstructive pulmonary disease (COPD) | licensing |
Respiratory diseases | Licensing agreement |
| 2012-03-21 | Stevenage BioScience Catalyst (UK) Kurma Life Sciences Partners (France) | collaboration |
Collaboration agreement | |||
| 2012-03-20 | Shire (UK-USA) Heptares (UK) | novel adenosine A2A antagonist | CNS diseases | licensing |
CNS diseases | Licensing agreement |
| 2012-03-19 | UCB (Belgium) Oxford University (UK) | serious diseases in immunology and neurology | R&D |
Immunological diseases - Neurological diseases | R&D agreement | |
| 2012-03-16 | AM-Pharma (The Netherlands) | nomination |
Inflammatory diseases | Nomination | ||
| 2012-03-15 | Ceva Santé Animale (France) ProBioGen (Germany) | AGE1.CR®avian cell line | licensing |
Veterinary medicine | Licensing agreement | |
| 2012-03-13 | Agennix (Germany) Royal DSM (The Netherlands) | talactoferrin | non small cell lung cancer | production |
Cancer Oncology | Production agreement |
| 2012-03-13 | GSK (UK) Epistem (UK) | biomarkers | fibrosis | collaboration |
Collaboration agreement | |
| 2012-03-13 | Vivalis (France) undisclosed European mid-sized biopharmaceutical company | EB66® cell line | undisclosed | licensing |
undisclosed | Licensing agreement |
| 2012-03-12 | Cosmo Pharmaceuticals (Italy) Intrepid Therapeutics (USA) | CB-03-01 (cortexolone 17alpha-propionate) | acne, alopecia | R&D |
Dermatological diseases | R&D agreement |
| 2012-03-12 | Horizon Discovery (UK) Rosalind Franklin University Medical Sciences - RFUMS (USA) | human cellular disease model of cystic fibrosis | cystic fibrosis | R&D |
Rare diseases - Genetic diseases | R&D agreement |
| 2012-03-08 | Qiagen (The Netherlands) KingMed Diagnostics (China) | digene HPV Test | marketing |
Cancer Oncology - Infectious diseases | Commercialisation agreement | |
| 2012-03-08 | Dr. Falk Pharma GmbH (Germany) Lipid Therapeutics (Germany) | LT-02 | ulcerative colitis | licensing |
Autoimmune diseases - Inflammatory diseases | Licensing agreement |
| 2012-03-07 | Sanofi (France) The Centre for Genomic Regulation (Centre de Regulació Genòmica - CRG) (Spain) | genetic diseases and rare diseases | R&D |
Rare diseases - Genetic diseases - Infectious diseases | R&D agreement | |
| 2012-03-07 | Lonza (Switzerland) LegoChem Biosciences (South Korea) | Light Path™ Discovery Services | R&D |
Technology - Services | Production agreement | |
| 2012-03-05 | Phosphate Therapeutics (UK) Medical Research council - MRC (UK) | PT20 | hyperphosphataemia | licensing |
Metabolic diseases - Renal diseases - Kidney diseases | Licensing agreement |
| 2012-03-02 | GSK (UK) Daiichi Sankyo (Japan) | vaccines | joint-venture |
Infectious diseases | Joint-venture agreement | |
| 2012-03-02 | Bachem (Switzerland) BioSpring (Germany) | oligonucleotide peptide conjugates | R&D |
Production agreement | ||
| 2012-02-29 | Lonza (Switzerland) Eclipse Therapeutics (USA) | ET-101 | cancer | development |
Cancer - Oncology | Production agreement |
